Catalog No.
KDC29901
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD221 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Cixutumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Cixutumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Cixutumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Cixutumumab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
125 - 4,000 ng/mL
Sensitivity
39.37 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
2,305.5 |
453.5 |
111.4 |
1,676.4 |
410.0 |
95.1 |
|
Standard deviation |
245.7 |
26.4 |
10.7 |
211.0 |
32.4 |
18.8 |
|
CV (%) |
10.7 |
5.8 |
9.6 |
12.6 |
7.9 |
19.8 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
IMC-A12, LY3012217, CAS: 947687-12-9
Background
Cixutumumab (IMC-A12) is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity for the treatment of solid tumors. This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from Dyax. Cixutumumab was well tolerated when used alone and in combination therapies, but its antitumor activity was low in the existing phase II clinical trials. An acceptable incidence of adverse effects supports further investigation of this drug, provided that it shows antitumor activity in combination with other drugs. Now, cixutumumab is involved in two cancer clinical trials, including esophageal cancer and breast cancer.
For research use only. Not for human or drug use.
